MedPath

A Phase II Study of Pemetrexed and Gefitinib in Chemotherapy Naive Patients with Non-Small Cell Lung Cancer Harboring Mutations of EGFR

Phase 2
Conditions
on-Small Cell Lung Cancer
Registration Number
JPRN-UMIN000003808
Lead Sponsor
Osaka Lung Cancer Study Group
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
26
Inclusion Criteria

Not provided

Exclusion Criteria

1) Using NSAIDs regularly. 2) Interstitial pneumonia/lung fibrosis on chest CT. 3) Previous drug allergy 4) History of poorly controlled pleural effusion, pericardial effusion and ascites. 5) Active infection. 6) Current Diarrhea. 7) Ileus or intestinal tract paralysis. 8) Symptomatic brain metastasis. 9) Active concomitant malignancy. 10) History of sever heart disease. 11) History of sever psychological disease. 12) Hoped to be pregnant/nursing. 13) Those judged to be not suitable by the attending physician.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
RR:response rate
Secondary Outcome Measures
NameTimeMethod
PFS: progression free survival OS: overall survival DCR: disease control rate AEs: adverse events
© Copyright 2025. All Rights Reserved by MedPath